Review findings

ARA-290 (Cibinetide): Neuroprotective Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

ARA-290 is derived from EPO structure but should not affect erythropoiesis CMP When: Baseline Why: Liver and kidney function baseline HbA1c When: Baseline Why: Baseline glycemic control (studied in type 2 diabetes neuropathy) Lipid panel When: Baseline Why: Baseline; some improvement in lipids observed in clinical trials Corneal confocal microscopy (if available) When: Baseline Why: Baseline nerve fiber density measurement CBC When: 2 weeks Why: Verify no erythropoietic stimulation (ARA-290 should not increase RBC) 💡 Key Considerations → Despite this, daily dosing is used because the innate repair receptor requires daily activation for nerve regeneration → Contraindication: Avoid in active cancer or myeloproliferative disorders due to EPO-derived mechanism; though ARA-290 is sp

Restore access No thanks, continue reading Related Reading Peptide EPO erythropoietin neuroprotective hormone Peptide Cerebrolysin neuroprotective peptide mixture Peptide Ara 290 peptide How ARA-290 works at the cellular level Overview of ARA-290 benefits and applications Scientific Details Molecular Formula C52H91N17O21 Molecular Weight 1257.35 Da CAS Number 1208243-50-8 Sequence QEQLERALNSS What is ARA-290? # ARA-290, also known as cibinetide, is a synthetic 11-amino acid peptide engineered from the three-dimensional structure of erythropoietin (EPO).

Mechanism of Action # ARA-290 selectively activates the innate repair receptor (IRR), a heteromeric complex composed of the erythropoietin receptor (EPOR) and the beta common receptor (CD131/betacR).

Research Overview # ARA-290 has progressed from preclinical studies into multiple Phase 2 clinical trials, making it one of the more clinically advanced neuroprotective peptides in development.

Important Considerations # ARA-290 is an investigational compound that has not yet received regulatory approval for any indication.

Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

PMID: 25387363): Clinical study showing that daily subcutaneous ARA-290 for 28 days improved hemoglobin A1c, lipid profiles, and neuropathic symptoms in patients with type 2 diabetes, with increased corneal nerve fiber density.

Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

What are the benefits of ARA-290?

Learn the basics of peptide science and research Related Peptides View all peptides → Healing & Tissue Repair Brain & Neuroprotection BPC-157 BPC-157 peptide comprehensive research guide.

Where to Find ARA-290 Compare all vendor prices → Research-grade suppliers verified by our scoring methodology.

Cognitive Enhancement Brain & Neuroprotection Semax Semax peptide guide: not FDA approved, but used in Russia since 2011.

Report an Error You Might Also Like Related content you may find interesting Peptide Neuroprotective Cerebrolysin Peptide Neuroprotective Davunetide Peptide Neuroprotective Nomlabofusp Peptide Immune Thymosin Alpha-1 Table of Contents What is ARA-290?

Significant improvement in SFN screening score at week 4 vs placebo No safety concerns identified ARA-290 2 mg IV three times weekly for 4 weeks was well tolerated ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density , published in Molecular Medicine (Dahan A et al., 2013;

dose: 2 mg · route: IV · duration: for 4 weeks · frequency: weekly

ted Side Effects Anecdotal ? 📋 Protocol Quick-Reference Neuropathic pain relief and small nerve fiber regeneration 💉 Dosing Amount 4 mg Frequency Once daily Duration 28 days 💊 Administration Route SC Schedule Once daily Timing Any time of day; no meal timing requirements ✓ Rotate injection sites 📅 Cycle Duration 28 days Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Store lyophilized peptide at -20C.

dose: 4 mg · cycle: Cycle · frequency: Once daily · reconstitution: reconstitution

Sarcoidosis-Associated Neuropathy # A 2012 randomized, double-blind, placebo-controlled pilot study in 22 sarcoidosis patients with small fiber neuropathy (SFN) showed that ARA-290 (2 mg IV, three times weekly for 4 weeks) significantly improved SFN screening scores compared to placebo, with no safety concerns identified.

dose: 2 mg · route: IV · duration: for 4 weeks · frequency: weekly

Diabetic Neuropathy # A clinical study in patients with type 2 diabetes showed that daily subcutaneous ARA-290 (4 mg) for 28 days improved hemoglobin A1c, lipid profiles, neuropathic symptoms, and corneal nerve fiber density.

dose: 4 mg · route: subcutaneous · duration: for 28 days · frequency: daily

Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

ARA-290 (Cibinetide): Neuroprotective Peptide Guide | Peptide Protocol Wiki Skip to main content 🧬 Peptide Protocol Wiki Peptides Side Effects New Learn Directory Tools Blog News About ⌘K ⌘K 🌱 New to Peptides?

Start the 7-step beginner guide Peptides Side Effects New Directory Learn Tools Blog News About ARA-290 📋 Overview 🧬 Molecule 🔄 Similar ⚠️ Side Effects 💉 Dosing 🔬 Research 🚨 Risks 👥 Community 📊 Community Data Home Peptides ARA-290 Brain & Neuroprotection Anti-Inflammatory phase2 ARA-290 Also known as: Cibinetide, Helix B Surface Peptide Research compiled by Peptide Protocol Wiki 📅 Updated February 8, 2026 Citations Verified TL;DR ARA-290 (cibinetide) is an 11-amino acid synthetic peptide derived from the tissue-protective domain of erythropoietin (EPO).

Consult the detailed side effects profile for full information.

Most reported side effects are mild and transient.

ted Side Effects Anecdotal ? 📋 Protocol Quick-Reference Neuropathic pain relief and small nerve fiber regeneration 💉 Dosing Amount 4 mg Frequency Once daily Duration 28 days 💊 Administration Route SC Schedule Once daily Timing Any time of day; no meal timing requirements ✓ Rotate injection sites 📅 Cycle Duration 28 days Repeatable Yes Preparation & Storage ✓ Ready-to-use — no reconstitution required Storage: Store lyophilized peptide at -20C.

Directory Peptide Vendors Analytics Labs Side Effects Database Report a Side Effect Learn Start Here What Are Peptides?

What are the side effects of ARA-290?

Reported side effects of ARA-290 include injection site reactions, headache, fatigue.

PMID: 24136731): Follow-up study demonstrating that 28 days of daily subcutaneous ARA-290 improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients with documented small nerve fiber loss.

FDA Fast Track for chronic low back pain. ⚠️ Medical Disclaimer This website is for educational and informational purposes only.

A follow-up 2013 study demonstrated that 28 days of daily subcutaneous ARA-290 improved neuropathic symptoms and increased corneal nerve fiber density in sarcoidosis patients.

ARA-290 is derived from EPO structure but should not affect erythropoiesis CMP When: Baseline Why: Liver and kidney function baseline HbA1c When: Baseline Why: Baseline glycemic control (studied in type 2 diabetes neuropathy) Lipid panel When: Baseline Why: Baseline; some improvement in lipids observed in clinical trials Corneal confocal microscopy (if available) When: Baseline Why: Baseline nerve fiber density measurement CBC When: 2 weeks Why: Verify no erythropoietic stimulation (ARA-290 should not increase RBC) 💡 Key Considerations → Despite this, daily dosing is used because the innate repair receptor requires daily activation for nerve regeneration → Contraindication: Avoid in active cancer or myeloproliferative disorders due to EPO-derived mechanism; though ARA-290 is sp

Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.

Improvement in hemoglobin A1c Improved lipid profiles Significant improvement in neuropathic symptoms Related Reading # ARA-290 research studies and evidence ARA-290 dosing protocols ARA-290 side effects profile BPC-157 research guide Semax research guide Stay current on ARA-290 research We summarize new studies, safety updates, and dosing insights — delivered biweekly.